Skip to main content
. Author manuscript; available in PMC: 2022 Apr 15.
Published in final edited form as: Antiviral Res. 2021 Aug 4;194:105158. doi: 10.1016/j.antiviral.2021.105158

Table 2.

Influenza A/PR/8/34 (H1N1) PB2 variants with reduced susceptibility to pimodivir, selected by passage in vitro (Byrn et al., 2015).

PB2 amino acid substitution Pimodivir susceptibility (mean EC50 ± SD, μM)a Fold change
WTb 0.003 ± 0.002 1
Q306H 0.56 ± 0.71 186
S324I 0.47 ± 0.071 157
S324N 0.38 ± 0.68 127
S324R 0.19 ± 0.23 63
F404Y 0.77 ± 0.50 257
N510T 0.40 ± 0.05 133
a

EC50 values were determined in a cell viability assay in MDCK cells.

b

WT, wild-type, pimodivir-susceptible.